Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

bitopertin

Roche Basel Switzerland

Roche’s Ocrevus is first primary progressive MS drug in EU

Analysts predict the drug could be a $3bn product by 2021

Roche and GE Healthcare plan ‘industry first’ digital platform

Co-developed clinical decision support software will begin with cancer and critical care

Roche Basel Switzerland

Roche buys cancer company Ignyta for $1.7bn

Pursues same oncology target that encouraged Bayer's recent deal with Loxo

Boehringer Ingelheim headquarters

Boehringer adds to pipeline again with €628m Autifony CNS deal

Bags rights to the GlaxoSmithKline spin-out's small-molecule drug for schizophrenia

- PMLiVE

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

Roche preps kidney cancer filing for Tecentriq/Avastin combo

Says treatment reduced risk of disease worsening compared to Sutent

- PMLiVE

Data backs up Roche’s Tecentriq/Avastin combo in lung cancer

Results will be used to pursue a first-line indication in NSCLC

- PMLiVE

Mylan gets first biosimilar Herceptin OK from FDA

Ogivri approved by US regulators for all of Roche blockbuster's indications

- PMLiVE

Roche offers diabetes digital health programme to UK patients

Partners with OurPath for its six-week lifestyle management programme

- PMLiVE

First Herceptin biosimilar cleared in Europe

Ontruzant is approved for all the same indications as Roche’s blockbuster

- PMLiVE

Lung cancer data gives Roche’s Tecentriq a boost

Will help its PD-L1 inhibitor compete with Merck & Co’s Keytruda

Roche Basel Switzerland

New data could unlock bigger market for Roche’s Hemlibra

Trial shows it ‘significantly’ reduced bleeds in some haemophilia A patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links